Drugs / Lozanoc
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02493738 | Jul → Oct 2015 | candidiasis, dermatomycosis, histoplasmosis, superficial mycosis | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02755857 | Jul → Dec 2016 | neutropenia | Mayne Pharma International Pty Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lozanoc | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02493738 ↗ |
| Route | Oral | “orally administered Lozanoc under fasted and fed condition in healthy male subjects” NCT02493738 ↗ |